PHILADELPHIA—The treatment of rheumatic diseases is often a double-edged sword: immunosuppressive regimens can be very effective in reducing disease activity, but the cost of such treatments may be seen in the form of increased risk of infection. At ACR Convergence 2022, the session titled ACR Guidelines for Vaccination in Patients with Rheumatic and Musculoskeletal Diseases…
Meghan Berkenstock, MD, summarized key clinical pearls related to uveitis and rheumatic diseases during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.
Scleromyxedema is a primary cutaneous mucinosis characterized by a diffuse and generalized papular skin eruption of mucinous deposits throughout the upper dermis. In addition to dermatologic manifestations, scleromyxedema may involve the cardiopulmonary, gastrointestinal, renal and nervous systems. Dermato-neuro syndrome (DNS) is a rare, severe neurologic complication of scleromyxedema.1,2 The pathogenesis of DNS is unknown, but…
Many a rheumatology consult has centered on a perplexing question: Does this patient have central nervous system (CNS) vasculitis? At the 2021 ACR State-of-the-Art Clinical Symposium, Rula Hajj-Ali, MD, FACP, professor of medicine and associate director of vasculitis care and research, Cleveland Clinic Lerner College of Medicine, discussed this topic in detail, providing a series…
NIH investigators describe key features and genetic causes of Mendelian interferonopathies, & treatment approaches that may indicate the efficacy of IFN inhibition.
In a 24-month clinical trial, tofacitinib proved safe and effective in combination with methotrexate in adult patients with RA…
Vasculitis is a group of chronic inflammatory diseases in which the blood vessel is the target of an immune reaction. They can be secondary to connective tissue disease, idiopathic or due to infection, neoplasm or drugs.1 Primary angiitis of the central nervous system (PACNS) is a rare syndrome characterized by inflammatory cell infiltration and necrosis…
AMSTERDAM—Low-grade inflammation in older adults can impede immune responsiveness, and researchers have shed light on how this happens. They have developed a short-term treatment that blocks inflammation and boosts the immune response, an expert said at EULAR: the Annual European Congress of Rheumatology. The findings were presented in a session on cellular senescence related to…
Upadacitinib proved safe and effective in RA patients who had inadequate responses to conventional disease-modifying anti-rheumatic drugs…
In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…